IP Verse

Compounds For Improved Viral Transduction - EP3269802

The patent EP3269802 was granted to Bluebird BIO on Oct 23, 2019. The application was originally filed on Sep 28, 2012 under application number EP17173567A. The patent is currently recorded with a legal status of "Revoked".

EP3269802

BLUEBIRD BIO
Application Number
EP17173567A
Filing Date
Sep 28, 2012
Status
Revoked
Nov 22, 2024
Grant Date
Oct 23, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SCRIPTJul 23, 2020DEMPSTERWITHDRAWN
HGFJul 21, 2020-WITHDRAWN

Patent Citations (48) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2004092535
DESCRIPTIONUS2004209878
DESCRIPTIONUS2006247214
DESCRIPTIONUS4873192
DESCRIPTIONUS5223409
DESCRIPTIONUS5399363
DESCRIPTIONUS5460964
DESCRIPTIONUS5466468
DESCRIPTIONUS5543158
DESCRIPTIONUS5635387
DESCRIPTIONUS5641515
DESCRIPTIONUS5677136
DESCRIPTIONUS5681599
DESCRIPTIONUS5716827
DESCRIPTIONUS5725871
DESCRIPTIONUS5750397
DESCRIPTIONUS5756353
DESCRIPTIONUS5759793
DESCRIPTIONUS5780045
DESCRIPTIONUS5804212
DESCRIPTIONUS5861488
DESCRIPTIONUS5864029
DESCRIPTIONUS5869039
DESCRIPTIONUS5877288
DESCRIPTIONUS5994136
DESCRIPTIONUS6013516
DESCRIPTIONUS6013769
DESCRIPTIONUS6051402
DESCRIPTIONUS6057117
DESCRIPTIONUS6608063
DESCRIPTIONUS6610719
DESCRIPTIONUS6670323
DESCRIPTIONUS6682907
DESCRIPTIONUS6747037
DESCRIPTIONUS7015037
DESCRIPTIONUS7901671
DESCRIPTIONWO0038663
DESCRIPTIONWO0112596
DESCRIPTIONWO02088346
DESCRIPTIONWO2006047476
DESCRIPTIONWO2007071456
DESCRIPTIONWO2007112084
DESCRIPTIONWO2008108741
DESCRIPTIONWO2008126932
DESCRIPTIONWO2010108028
OPPOSITIONWO0023567
OPPOSITIONWO2010054271
SEARCHWO2004098531

Non-Patent Literature (NPL) Citations (88) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ADCOCK, BRITISH JOURNAL OF PHARMACOLOGY, (2007), vol. 150, pages 829 - 831-
DESCRIPTION- BARNES,C; BALASUBRAMANIAN, S., CURR. OPIN. CHEM. BIOL., (2000), vol. 4, pages 346 - 350-
DESCRIPTION- BEARD ET AL., J CLIN INVEST., (2010), vol. 120, no. 7, pages 2345 - 2354-
DESCRIPTION- BELL ET AL., CELL, (1999), vol. 98, page 387-
DESCRIPTION- BOHM, H. J; STAHL, M., CURR. OPIN. CHEM. BIOL., (2000), vol. 4, pages 283 - 286-
DESCRIPTION- BURGESS-BEUSSE ET AL., PROC. NATL. ACAD. SCI., USA, (2002), vol. 99, page 16433-
DESCRIPTION- CABILLY, S., MOL. BIOTECHNOL, (1999), vol. 12, pages 143 - 148-
DESCRIPTION- CANE, D. E. ET AL., SCIENCE, (1998), vol. 282, pages 63 - 68-
DESCRIPTION- CARTIER, SCIENCE, (2009), vol. 326, no. 5954, pages 818 - 23-
DESCRIPTION- CAVAZZANA-CALVO ET AL., NATURE, (2010), vol. 467, no. 7313, pages 318 - 322-
DESCRIPTION- CHUNG ET AL., CELL, (1993), vol. 74, page 505-
DESCRIPTION- CHUNG ET AL., PNAS, (1997), vol. 94, page 575-
DESCRIPTION- CLEVER ET AL., J. OF VIROLOGY, (1995), vol. 69, no. 4, pages 2101 - 2109-
DESCRIPTION- CORNETTA ET AL., CANCER GENE THER., (2006), vol. 13, no. 9, pages 886 - 895-
DESCRIPTION- CULLEN ET AL., CELL, (1991), vol. 58, page 423-
DESCRIPTION- CULLEN ET AL., J. VIROL., (1991), vol. 65, page 1053-
DESCRIPTION- CZARNICK, A. W.; KEENE, J. D, CURRO BIOL., (1998), vol. 8, pages R705 - R707-
DESCRIPTION- DOLLE, R. E, J. COMB. CHEM., (2000), vol. 2, pages 383 - 433-
DESCRIPTION- DOLLE, R. E., MOL. DIVERS., (1998), vol. 4, pages 233 - 256-
DESCRIPTION- DOLLE, R. E; NELSON, K. H., J. COMB. CHEM., (1999), vol. 1, pages 235 - 282-
DESCRIPTION- DUNBAR ET AL., HUM GENE THER., (1998), vol. 9, no. 17, pages 2629 - 2640-
DESCRIPTION- FLOYD,C D. ET AL., PROG. MED. CHEM., (1999), vol. 36, pages 91 - 168-
DESCRIPTION- FURUMAI ET AL., PNAS, (2001), vol. 98, no. 1, pages 87 - 92-
DESCRIPTION- GLOVER, DNA Cloning: A Practical Approach, vol. I, II-
DESCRIPTION- GORE ET AL., CANCER RESEARCH, (2006), vol. 66, pages 6361 - 6369-
DESCRIPTION- HALL, D. G., NAT. BIOTECHNOL., (2000), vol. 18, pages 262 - 262-
DESCRIPTION- HAN ET AL., IMMUNOLOGY LETTERS, (2007), vol. 108, pages 143 - 150-
DESCRIPTION- HOUGHTEN, R. A., ANN. REV. PHARMACOL. TOXICOL., (2000), vol. 40, pages 273 - 282-
DESCRIPTION- HUANG; YEN, MOL. CELL. BIOL., (1995), vol. 5, page 3864-
DESCRIPTION- HUC, I.; NGUYEN, R., COMB. CHEM. HIGH THROUGHPUT SCREEN, (2001), vol. 4, pages 53 - 74-
DESCRIPTION- IMREN, PROC NATL ACAD SCI USA., (2002), vol. 99, no. 22, pages 14380 - 14385-
DESCRIPTION- IRIONS ET AL., NATURE BIOTECHNOLOGY, (2007), vol. 25, pages 1477 - 1482-
DESCRIPTION- JACKSON ET AL., TRENDS BIOCHEM SCI, (1990), vol. 15, no. 12, pages 477 - 83-
DESCRIPTION- JACKSON; KAMINSKI, RNA, (1995), vol. 1, no. 10, pages 985 - 1000-
DESCRIPTION- J. H. JANDL, Blood: Textbook of Hematology, 2nd ed., LITTLE, BROWN AND COMPANY, (1996), pages 544 - 545-
DESCRIPTION- KELLY ET AL., NATURE CLINICAL PRACTICE ONCOLOGY, (2005), vol. 2, pages 150 - 157-
DESCRIPTION- KOBAYASHI, S., CURR. OPIN. CHEM. BIOL., (2000), vol. 4, pages 338 - 345-
DESCRIPTION- KOPYLOV, A. M.; SPIRIDONOVA, V. A., MOL. BIOL. (MOSK, (2000), vol. 34, pages 1097 - 1113-
DESCRIPTION- KOZAK, CELL, (1986), vol. 44, no. 2, pages 283 - 92-
DESCRIPTION- KOZAK, NUCLEIC ACIDS RES., (1987), vol. 15, no. 20, pages 8125 - 48-
DESCRIPTION- KUNDU, B ET AL., PROG. DRUG RES., (1999), vol. 53, pages 89 - 156-
DESCRIPTION- KUNKEL ET AL., METHODS IN ENZYMOL, (1987), vol. 154, pages 367 - 382-
DESCRIPTION- KUNKEL, PROC. NATL. ACAD. SCI. USA., (1985), vol. 82, pages 488 - 492-
DESCRIPTION- LANDY, CURRENT OPINION IN BIOTECHNOLOGY, (1993), vol. 3, pages 699 - 707-
DESCRIPTION- LAZO, J. S.; WIPF, P, J. PHARMACOL. EXP. THER., (2000), vol. 293, pages 705 - 709-
DESCRIPTION- LEPRE,C A, DRUG DISCOV. TODAY, (2001), vol. 6, pages 133 - 140-
DESCRIPTION- LEPRE, ENJALBAL,C ET AL., MASS SEPTROM REV., (2000), vol. 19, pages 139 - 161-
DESCRIPTION- LEVASSEUR, BLOOD, (2003), vol. 102, pages 4312 - 4319-
DESCRIPTION- LIU ET AL., GENES DEV., (1995), vol. 9, page 1766-
DESCRIPTION- LOWE, G., NAT. PROD. REP, (1999), vol. 16, pages 641 - 651-
DESCRIPTION- LOWY ET AL., CELL, (1990), vol. 22, pages 817 - 823-
DESCRIPTION- MAGUIRE ET AL., N Engl J, (2008), vol. 358, page 2240-
DESCRIPTION- MALIK ET AL., ANN NYACAD SCI., (2005), vol. 1054, pages 238 - 249-
DESCRIPTION- MAY ET AL., NATURE, (2000), vol. 406, no. 6791, pages 82 - 86-
DESCRIPTION- MILLER, NATURE, (2000), vol. 357, pages 455 - 460-
DESCRIPTION- MILSOM ET AL., CANCER RES., (2008), vol. 68, no. 15, pages 6171 - 6180-
DESCRIPTION- MUNSTER ET AL., JOURNAL OF CLINICAL ONCOLOGY, (2007), vol. 25, no. 18S, page 1065-
DESCRIPTION- MYERS, P. L., CURR. OPIN. BIOTECHNOL., (1997), vol. 8, pages 701 - 707-
DESCRIPTION- N. R. LANDAU ET AL., J. VIROL., (1992), vol. 66, pages 5110 - 5113-
DESCRIPTION- PAWLIUK ET AL., SCIENCE, (2001), vol. 294, no. 5550, pages 2368 - 2371-
DESCRIPTION- PENG, S. X, BIOMED. CHROMATOGR., (2000), vol. 14, pages 430 - 441-
DESCRIPTION- PLUCKTHUN, A.; CORTESE, R., BIOL. CHEM., (1997), vol. 378, page 443-
DESCRIPTION- SANTONI DE SIO; NALDINI, METHODS MOL BIOL., (2009), vol. 506, pages 59 - 70-
DESCRIPTION- SAUER, B., CURRENT OPINION IN BIOTECHNOLOGY, (1994), vol. 5, pages 521 - 527-
DESCRIPTION- SIRIN ET AL., GENE, (2003), vol. 323, page 67-
DESCRIPTION- WEBER, L., CURR. OPIN. CHEM. BIOL., (2000), vol. 4, pages 295 - 302-
DESCRIPTION- WIGLER ET AL., CELL, (1977), vol. 11, pages 223 - 232-
DESCRIPTION- Y. SONEOKA ET AL., NUCL. ACIDS RES., (1995), vol. 23, pages 628 - 633-
DESCRIPTION- ZENNOU ET AL., CELL, (2000), vol. 101, page 173-
DESCRIPTION- ZHAN ET AL., HUM. GENET., (2001), vol. 109, page 471-
DESCRIPTION- ZHU ET AL., CURRENT MEDICINAL CHEMISTRY, (2003), vol. 3, no. 3, pages 187 - 199-
DESCRIPTION- ZUFFEREY ET AL., J. VIROL., (1999), vol. 73, page 2886-
OPPOSITION- JONATHAN G. HOGGATT, "EICOSANOID REGULATION OF HEMATOPOIETIC STEM AND PROGENITOR CELL FUNCTION", PhD Thesis, (20100721), URL: http://hdl.handle.net/1805/2206, XP055766898-
OPPOSITION- JONATHAN G HOGGATT, "Eicosanoid Regulation of Hematopoietic Stem and Progenitor Cell Function", thesis, (20100721), pages ii-xx, 1 - 274, URL: http://hdl.handle.net/1805/2206, XP055766898-
OPPOSITION- Li M; Husic N; Lin Y; Christensen H; Malik I; McIver S; Daniels C M L; Harris D A; Kotzbauer P T; Goldberg M P; Snider B J, "Optimal promoter usage for lentiviral vector-mediated transduction of cultured central nervous system cells", JOURNAL OF NEUROSCIENCE METHODS,, (20100530), vol. 189, no. 1, pages 56 - 64, XP027037853-
OPPOSITION- Marc Giry-Laterriere, Els Verhoeyen, and Patrick Salmon, "Chapter 8 Lentiviral Vectors", Marc Giry-Laterriere, Els Verhoeyen, and Patrick Salmon, Otto-Wilhalm Merten and Mohamed Al-Rubeai, Viral Vectors for Gene Therapy: Methods and Protocols,Methods in Molecular Biology, vol. 737,, Springer Science+Business Media, LLC, (20110402), vol. 737, pages 183 - 209, ISBN 978-1-61779-094-2, XP055766911-
OPPOSITION- Melania Tesio, A Loretta Gammaitoni, A Monica Gunetti, B Valeria Leuci, A Ymera Pignochino, A Noela Jordaney, A Sonia Capellero, A Cristina Cammarata, A Luisa Caione, A Giuseppe Migliaretti, C Franca Fagioli, B Antonio Tabilio, D,E Massimo Aglietta, A Wanda Piacibello, "Sustained Long-Term Engraftment and Transgene Expression of Peripheral Blood CD34+ Cells Transduced with Third-Generation Lentiviral Vectors", Stem Cells, (20080000), vol. 26, no. 6, pages 1620 - 1627, XP055766903-
OPPOSITION- SUTTON R E, ET AL., "TRANSDUCTION OF HUMAN PROGENITOR HEMATOPOIETIC STEM CELLS BY HUMAN IMMUNODEFICIENCY VIRUS TYPE 1-BASED VECTORS IS CELL CYCLE DEPENDENT", Journal of Virology, US, (19990501), vol. 73, no. 05, ISSN 0022-538X, pages 3649 - 3660, XP002937676-
OPPOSITION- Wolfram Goessling, Robyn S Allen, Xiao Guan, Ping Jin, Naoya Uchida, Michael Dovey, James M Harris, Mark E Metzger, Aylin C Bonifacino, David Stroncek, Joseph Stegner, Myriam Armant, Thorsten Schlaeger, John F Tisdale, Leonard I Zon, Robert E Donahue, and Trista E North, "Prostaglandin E2 enhances engraftment of human cord blood stem cells and shows long-term safety in preclinical non-humanprimate transplant models /NIH Author Manuscript/", Cell Stem Cell/ PMC, (20111008), pages 1 - 24, XP055766893-
OPPOSITION- Liu Y; Hangoc G; Campbell T B; Goodman M; Tao W; Pollok K; Srour E F; Broxmeyer H E, "Identification of parameters required for efficient lentiviral vector transduction and engraftment of human cord blood CD34^+ NOD/SCID-repopulating cells", EXPERIMENTAL HEMATOLOGY, (20080000), vol. 36, pages 947 - 956, XP022940498
OPPOSITION- Louis M. Pelus; Jonathan Hoggatt;, "Pleiotropic effects of prostaglandin Ein hematopoiesis; prostaglandin Eand other eicosanoids regulate hematopoietic stem and progenitor cell function", Prostaglandins and Other Lipid Mediators, US, (20110614), vol. 96, no. 1, doi:10.1016/j.prostaglandins.2011.06.004, ISSN 1098-8823, pages 3 - 9, XP028108764
OPPOSITION- Wolfram Goessling; Allen Robyn S; Guan Xiao; Jin Ping; Uchida Naoya; Dovey Michael; Harris James M; Metzger Mark E; Bonifacino Aylin C; Stroncek David; Stegner Joseph; Armant Myriam; Schlaeger Thorsten; Tisdale John F; Zon Leonard I; Donahue Robert E; North Trista E, "Prostaglandin E2 Enhances Human Cord Blood Stem Cell Xenotransplants and Shows Long-Term Safety in Preclinical Nonhuman Primate Transplant Models /Supplemental Information /", Cell Stem Cell, (2011), pages 1 - 16, XP055632946
OPPOSITION- Uchida N; Hsieh M M; Hayakawa J; Madison C; Washington K N; Tisdale J F, "Optimal conditions for lentiviral transduction of engrafting human CD34+ cells", Gene Therapy, (20110505), vol. 18, no. 11, pages 1078 - 1086, XP055206476
OPPOSITION- HAYAKAWA J et al., "Transient in vivo beta-globin production after lentiviral gene transfer to hematopoietic stem cells in the non-human primate", HUMAN GENE THERAPY,, (20090600), vol. 20, no. 6, pages 563 - 572, XP002616805
OPPOSITION- N. Cartier, S. Hacein-Bey-Abina, C. C. Bartholomae, G. Veres, M. Schmidt, I. Kutschera, M. Vidaud, U. Abel, L. Dal-Cortivo, L. Caccavelli, N. Mahlaoui, V. Kiermer, D. Mittelstaedt, C. Bellesme, N. Lahlou, F. Lefrere, S. Blanche, M. Audit, E. Payen, P. Leboulch, B. L'homme, P. Bougneres, C. Von Kalle, A. Fischer, M. Cavazzana-Calvo, P. Aubourg, "Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy", Science, (20091106), vol. 326, no. 5954, doi:10.1126/science.1171242, ISSN 00368075, pages 818 - 823, XP055018846
OPPOSITION- Naoya Uchida, Kareem N Washington, Jun Hayakawa, Matthew M Hsieh, Aylin C Bonifacino, Allen E Krouse, Mark E Metzger, Robert E Donahue, John F Tisdale, "Development of a human immunodeficiency virus type 1-based lentiviral vector that allows efficient transduction of both human and rhesus blood cells", J. Virol., (20091000), vol. 83, no. 19, pages 9854 - 9862, XP055766896
OPPOSITION- Piacibello Wanda; Bruno Stefania; Sanavio Fiorella; Droetto Sara; Gunetti Monica; Ailles Laurie; de Sio Francesca San, "Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice", Blood, (20020000), vol. 100, no. 13, pages 4391 - 4400, XP009110673
SEARCH- MOSTOSLAVSKY ET AL, "Efficiency of transduction of highly purified murine hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of minimal in vitro manipulation", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, (20050601), vol. 11, no. 6, doi:10.1016/J.YMTHE.2005.01.005, ISSN 1525-0016, pages 932 - 940, XP005002713 [I] 1-15 * figure 1c *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents